Building off the previous session from the Life Sciences IG, this member benefit is part of a series from both the Life Sciences and Physician Issues IG that will explore issues relating to GLP1 inhibitors from all angles. This session will focus on FDA approval and regulation of this class of medications, the historic shortage, the "end" of the shortage, and what that means for the industry moving forward.
